Refer a Patient

BEST-NMOSD is enrolling AQP4+ NMOSD patients across international sites. We've streamlined the referral process to make it as simple as possible for busy clinicians.

Referral Process

Check Basic Eligibility

Confirm AQP4-IgG positivity and NMOSD diagnosis per 2025 IPND criteria. Prior treatment with any immunotherapy is permitted.

Contact the Study Team

Fill out the referral form below or email us directly. We’ll arrange a pre-screening review to confirm eligibility.

Pre-Screening & Consent

Our team reviews the patient’s medical records. If eligible, the patient is scheduled for a screening visit with informed consent.

Enrollment & Treatment

Randomization occurs at screening. Insurance approval for the assigned study medication begins immediately. First dose within 90 days.

Study Endpoints

NCT07010302 — Phase 4, multicenter, international, randomized superiority trial

Primary Endpoint

Composite Treatment Failure

1.Time to adjudicated relapse (TAR)
OR
2.Time to protocol-defined safety or tolerability failure

Secondary Endpoints

Effectiveness

• Time to adjudicated relapse
• Annualized relapse rate
• Proportion receiving rescue therapy

Disability

• Composite confirmed disability progression
• EDSS (≥1.0 if baseline ≤5.5; ≥0.5 if >5.5)
• MSFC: T25FW, 9-HPT, SDMT (≥20% worsening)
• HCVA/LCVA (≥7-letter decrease)

Quality of Life

• EQ-5D-3L, FSMC, NEI-VFQ-25
• PROMIS Depression SF, Pain NRS
• PROMIS Pain Interference
• TSQM-II (treatment satisfaction)

Safety

• TEAEs (graded per CTCAE)
• Annualized hospitalization rate
• Time to safety/tolerability failure

Exploratory Endpoints

Health Economics

• COST (financial toxicity)
• WPAI (work productivity)
• Direct costs (medications, co-pays, visits)
• Indirect costs (work loss, caregiver burden)

Trial Design

• 1:1 Rituximab vs. CIS
• CIS sub-randomized 1:1:1
• Adaptive design with interim analyses
• Observational cohort (n=380) for dynamic borrowing
• Blinded relapse adjudication committee
• Independent DSMB oversight

Ready to Refer?

Contact the study team to discuss a potential referral or learn more about the trial. We aim to respond within 1 business day.

Submit a Referral bestnmosd@mgh.harvard.edu

Clinical Coordinating Center

Mass General Brigham

Harvard Medical School

Data Coordinating Center

Charité Berlin

NEMOS Network